MetaVia to Showcase Groundbreaking Liver Treatment Research at AASLD 2025
MetaVia Inc., a clinical-stage biotechnology company focused on innovating treatments for cardiometabolic diseases, has announced that it will present an important poster on its investigational drug Vanoglipel (DA-1241) at the prestigious American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025. This event will take place in Washington, D.C., from November 7-11, 2025.
The research presented highlights a compelling abstract that showcases the potential benefits of Vanoglipel as a G-Protein-Coupled Receptor 119 (GPR119) agonist. The title of the poster is "Vanoglipel (DA-1241), a GPR119 Agonist, Demonstrates Hepatoprotective Effects Through Improving Inflammation and Metabolism in the Liver: A 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients". This work will be presented by Dr. Rohit Loomba, Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at the University of California at San Diego.
The poster presentation is scheduled for November 10, 2025, from 1:00 PM to 2:00 PM ET in Hall DE of the Convention Center. It embodies a significant scientific advancement that could potentially redefine the management of liver-related diseases, particularly Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Vanoglipel is garnering attention for its multi-faceted mechanism of action, which enhances the release of critical gut peptides such as GLP-1, GIP, and PYY. These peptides are pivotal in regulating metabolic processes, contributing to improved glucose control, enhanced lipid profiles, and beneficial impacts on liver inflammation. In preclinical trials, DA-1241 has consistently demonstrated efficacy in reducing hepatic fat accumulation, inflammation, and fibrosis, along with improved glucose regulation in various animal models.
In phases 1a, 1b, and 2a clinical trials, Vanoglipel was well tolerated by both healthy individuals and those suffering from type 2 diabetes mellitus (T2DM). Notably, in a Phase 2a clinical trial, the drug showed not only its glucose-lowering capabilities but also direct action on liver health, emphasizing its potential as a dual-action treatment for patients with MASH.
To put it into perspective, the increase in cases of MASH is becoming a notable public health concern, often spanning a spectrum of diseases from simple steatosis to cirrhosis, making the advancement of effective therapies like Vanoglipel crucial. MetaVia's focus on innovative therapeutics aims to bridge the gap between unmet medical needs and existing treatment paradigms.
The research community is eagerly looking forward to the full presentation of results, and interested persons can find the poster displayed at the convention and on MetaVia's website after the event concludes. Requirements for therapies targeting gut hormone pathways are gaining recognition, especially given the increasing prevalence of metabolic diseases, making this presentation a noteworthy development in the pharmaceutical landscape.
About MetaVia: Founded with the mission of transforming cardiometabolic health, MetaVia focuses on developing treatments that address major gaps in the industry. The company is concurrently advancing another drug candidate, DA-1726, designed for obesity management, which demonstrates best-in-class weight loss and glucose control during clinical evaluations.
For ongoing updates and more details, please visit MetaVia's official website at www.metaviatx.com, where interested parties can find more about their innovative research initiatives and partnerships aimed at tackling complex health issues affecting patients today.
The research presented highlights a compelling abstract that showcases the potential benefits of Vanoglipel as a G-Protein-Coupled Receptor 119 (GPR119) agonist. The title of the poster is "Vanoglipel (DA-1241), a GPR119 Agonist, Demonstrates Hepatoprotective Effects Through Improving Inflammation and Metabolism in the Liver: A 16-week Randomized Placebo-Controlled Trial in Presumed MASH Patients". This work will be presented by Dr. Rohit Loomba, Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at the University of California at San Diego.
The poster presentation is scheduled for November 10, 2025, from 1:00 PM to 2:00 PM ET in Hall DE of the Convention Center. It embodies a significant scientific advancement that could potentially redefine the management of liver-related diseases, particularly Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Vanoglipel is garnering attention for its multi-faceted mechanism of action, which enhances the release of critical gut peptides such as GLP-1, GIP, and PYY. These peptides are pivotal in regulating metabolic processes, contributing to improved glucose control, enhanced lipid profiles, and beneficial impacts on liver inflammation. In preclinical trials, DA-1241 has consistently demonstrated efficacy in reducing hepatic fat accumulation, inflammation, and fibrosis, along with improved glucose regulation in various animal models.
In phases 1a, 1b, and 2a clinical trials, Vanoglipel was well tolerated by both healthy individuals and those suffering from type 2 diabetes mellitus (T2DM). Notably, in a Phase 2a clinical trial, the drug showed not only its glucose-lowering capabilities but also direct action on liver health, emphasizing its potential as a dual-action treatment for patients with MASH.
To put it into perspective, the increase in cases of MASH is becoming a notable public health concern, often spanning a spectrum of diseases from simple steatosis to cirrhosis, making the advancement of effective therapies like Vanoglipel crucial. MetaVia's focus on innovative therapeutics aims to bridge the gap between unmet medical needs and existing treatment paradigms.
The research community is eagerly looking forward to the full presentation of results, and interested persons can find the poster displayed at the convention and on MetaVia's website after the event concludes. Requirements for therapies targeting gut hormone pathways are gaining recognition, especially given the increasing prevalence of metabolic diseases, making this presentation a noteworthy development in the pharmaceutical landscape.
About MetaVia: Founded with the mission of transforming cardiometabolic health, MetaVia focuses on developing treatments that address major gaps in the industry. The company is concurrently advancing another drug candidate, DA-1726, designed for obesity management, which demonstrates best-in-class weight loss and glucose control during clinical evaluations.
For ongoing updates and more details, please visit MetaVia's official website at www.metaviatx.com, where interested parties can find more about their innovative research initiatives and partnerships aimed at tackling complex health issues affecting patients today.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.